newsfilter
← Latest News
GlobeNewswire·

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor ("Ahr") agonist in development for ulcerative colitis, to its pipeline Closed